Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: A cross-sectional study

Po Chung Cheng 1, Shang Ren Hsu Correspond., 1, Yun Chung Cheng 2, Yu Hsiu Liu 3

1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua City, Changhua County, Taiwan
2 Department of Radiology, Taichung Veterans General Hospital, Taichung, Taiwan
3 Department of Accounting and Information Systems, National Taichung University of Science and Technology, Taichung, Taiwan

Corresponding Author: Shang Ren Hsu
Email address: wintry_morn@msn.com

Background. Individuals with type 2 diabetes (T2D) are at an increased risk of coronary heart disease (CHD). Diabetic complications have recently been associated with a measure of glucose metabolism known as the hemoglobin glycation index (HGI). Currently there is insufficient information regarding a potential link between HGI and cardiovascular disease. This study aimed to investigate the relationship between HGI and extent of CHD in individuals with T2D. Methods. This cross-sectional study screened individuals visiting the endocrinology clinic between June 2012 and May 2016 for eligibility. Enrollment criteria included individuals above 21 years of age with T2D diagnosed in the preceding ten years. Candidates with hemoglobin disorders, pregnancy, and existing coronary artery disease were excluded. Fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) were sampled three months prior to angiography. The regression equation of predicted HbA1c = 0.008 x FPG + 6.28 described the linear relationship between these variables. HGI was calculated as the difference between the measured HbA1c and predicted HbA1c. Participants were classified into two groups according to the presence of supranormal (≥ 0) or subnormal HGI (< 0). Results. Among 423 participants, people with supranormal HGI harbored an increased prevalence of multiple vessel disease relative to those with subnormal HGI (Odds ratio (OR): 3.9, 95% confidence interval (CI): 2.64 – 5.98, P < 0.001). Moreover, individuals with supranormal HGI more frequently demonstrated lesions involving the left anterior descending artery (OR: 3.0, 95% CI: 1.97 – 4.66, P < 0.001). The intergroup difference in mean HbA1c was statistically nonsignificant (7.5 ± 1.0 % versus 7.4 ± 1.1 %, P = 0.80). Discussion. This study demonstrated that HGI correlated with the extent of CHD in individuals with T2D. People with supranormal HGI harbored a higher prevalence of extensive cardiovascular disease compared to those with subnormal HGI. The relationship between HGI and extent of CHD enables cardiovascular risk stratification...
in at risk individuals. Overall, HGI provides useful information concerning cardiovascular risk in clinical practice.
Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: A cross-sectional study

Po Chung Cheng\textsuperscript{1,†}, Shang Ren Hsu\textsuperscript{1}, Yun Chung Cheng\textsuperscript{2,†}, Yu Hsiu Liu\textsuperscript{3}

\textsuperscript{1} Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanxiao St., Changhua City, Changhua County, Taiwan
\textsuperscript{2} Department of Radiology, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Section 4, Taichung, Taiwan
\textsuperscript{3} Department of Accounting and Information Systems, National Taichung University of Science and Technology, 129 San Min Rd., Taichung, Taiwan

\textsuperscript{†} Equal contribution to the study

Corresponding author: Shang-Ren Hsu
Email address: wintry_morn@msn.com
**Background.** Individuals with type 2 diabetes (T2D) are at an increased risk of coronary heart disease (CHD). Diabetic complications have recently been associated with a measure of glucose metabolism known as the hemoglobin glycation index (HGI). Currently there is insufficient information regarding a potential link between HGI and cardiovascular disease. This study aimed to investigate the relationship between HGI and extent of CHD in individuals with T2D.

**Methods.** This cross-sectional study screened individuals visiting the endocrinology clinic between June 2012 and May 2016 for eligibility. Enrollment criteria included individuals above 21 years of age with T2D diagnosed in the preceding ten years. Candidates with hemoglobin disorders, pregnancy, and existing coronary artery disease were excluded. Fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) were sampled three months prior to angiography. The regression equation of predicted HbA1c = 0.008 x FPG + 6.28 described the linear relationship between these variables. HGI was calculated as the difference between the measured HbA1c and predicted HbA1c. Participants were classified into two groups according to the presence of supranormal (≥ 0) or subnormal HGI (< 0).

**Results.** Among 423 participants, people with supranormal HGI harbored an increased prevalence of multiple vessel disease relative to those with subnormal HGI (Odds ratio (OR): 3.9, 95% confidence interval (CI): 2.64 – 5.98, P < 0.001). Moreover, individuals with supranormal HGI more frequently demonstrated lesions involving the left anterior descending artery (OR: 3.0, 95% CI: 1.97 – 4.66, P < 0.001). The intergroup difference in mean HbA1c was statistically nonsignificant (7.5 ± 1.0 % versus 7.4 ± 1.1 %, P = 0.80).

**Discussion.** This study demonstrated that HGI correlated with the extent of CHD in individuals with T2D. People with supranormal HGI harbored a higher prevalence of extensive cardiovascular disease compared to those with subnormal HGI. The relationship between HGI and extent of CHD enables cardiovascular risk stratification in at risk individuals. Overall, HGI
provides useful information concerning cardiovascular risk in clinical practice.

Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: A cross-sectional study

1 Introduction
Type 2 diabetes mellitus (T2D) is a developing epidemic that affects a substantial proportion of the adult population (Chen, Magliano & Zimmet, 2011). Changes in dietary habit, urbanization, and sedentary lifestyle contribute to an increasing incidence of the disease (Yang et al., 2010). Hyperglycemia exerts detrimental effects on blood vessels, as evidenced by a predisposition to develop retinopathy, nephropathy, and coronary heart disease (CHD) (Mohammedi et al., 2017).

These vascular complications profoundly influence the quality of life in affected individuals. Specifically, individuals with T2D are at risk of developing cardiovascular disease (Shah et al., 2015), which accounts for nearly sixty percent of diabetes related mortality (Kalofoutis et al., 2007). Although glycemic control as represented by glycated hemoglobin A1c (HbA1c) influences vascular disease, this association is not particularly robust (Laakso, 2010). Investigators have proposed that elements of hyperglycemia not captured by HbA1c measurement may modify cardiovascular risk (Fox, 2010).

The hemoglobin glycation index (HGI) is an indicator of glucose metabolism linked to diabetic complications (Soros et al., 2010). HGI correlated with a composite index of cardiac, cerebral, and peripheral vascular events in a recent study involving individuals with T2D (Nayak, 2013). Specifically, this glycation index may correlate with cardiovascular disease risk. This study investigated the relationship between HGI and extent of coronary vascular disease in people with T2D.

2 Materials and Methods

2.1 Study population
This cross-sectional study screened patients visiting the endocrinology clinic at Changhua Christian Hospital, Changhua City, Taiwan, between June 2012 and May 2016 for eligibility. Enrollment criteria included individuals exceeding 21 years of age, with T2D diagnosed in the preceding ten years, who received hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors since diabetes onset and underwent coronary angiography (CAG) during the study period. Exclusion criteria involved people who had undertaken CAG prior to the study, those with existing CHD, or who lacked concomitant HbA1c and fasting plasma glucose (FPG) measurements. Candidates with hemoglobin disorders, pregnancy, and congenital coronary artery abnormalities were also ineligible. Decision to perform coronary artery survey was made by cardiologists based on high risk findings on non-invasive testing or high pre-test probability of coronary artery disease. All participants provided written informed consent for CAG. The study was approved by the Institutional Review Board of Changhua Christian Hospital (CCH IRB number: 161111).

2.2 Calculation of HGI

Concomitant HbA1c and FPG measurements from all participants were graphed to establish the linear relationship between these variables, as shown in Figure 1, from which the regression equation of predicted HbA1c = 0.008 x FPG + 6.28 was derived. Individual FPG in milligrams per deciliter was substituted into this linear regression equation to derive the predicted HbA1c. HGI was calculated as the difference between the measured HbA1c and predicted HbA1c (Hempe et al., 2015). Supranormal HGI was defined as levels above or equivalent to zero, whereas subnormal HGI designated values below zero.
2.3 Classification of CHD

The extent of vascular disease involving the left anterior descending, left circumflex, and right coronary arteries was documented by CAG. Significant stenosis was defined as more than fifty percent narrowing of the diseased vascular segment compared to a proximal or distal normal segment (Leopold & Faxon, 2015). Single vessel disease was defined as one or more stenotic lesions in one of the major coronary arteries, whereas multiple vessel disease involved lesions in two or more of the coronary arteries (Tazaki et al., 2013). Arteriosclerosis described the observation that none of the stenotic lesions resulted in more than fifty percent narrowing of the major coronary arteries.

2.4 Statistical analysis

Baseline characteristics including age, gender, lipid profile, mean HbA1c, and cigarette smoking were compared between the HGI subgroups. Intergroup comparisons were made using Student’s t test for continuous variables and Pearson’s χ² test for categorical variables. For the HGI subgroups, the prevalence of multiple vessel disease as opposed to single vessel disease or arteriosclerosis was compared using Pearson’s χ² test. Tests of statistical significance were based on a two-tailed P < 0.05. Statistical analysis was performed using Statistical Package for the Social Sciences (version 22.0, SPSS, Chicago, IL). A multivariate regression analysis was performed to evaluate the contribution of HGI and other risk factors to CHD. A logistic regression analysis adjusted for confounders demonstrated the association between the HGI subgroups and extent of cardiovascular disease.

3 Results
Initially 480 individuals with T2D were screened for eligibility. Twenty patients were excluded due to lack of HMG-CoA reductase inhibitor prescription, 32 individuals had received CAG prior to the study and were ineligible, and five candidates were excluded due to absence of concomitantly measured HbA1c and FPG. Figure 2 illustrates the enrollment process of this study.

The study enrolled 423 individuals who were classified according to the presence of either supranormal (≥ 0) or subnormal HGI (< 0). Baseline characteristics including age, gender, and kidney function were similar between groups, as summarized in Table 1. Levels of low-density lipoprotein cholesterol, presence of cigarette smoking, and degree of systolic blood pressure were also comparable. The intergroup difference in mean HbA1c was nonsignificant (7.5 ± 1.0 % versus 7.4 ± 1.1 %, \( P = 0.80 \)), and both HGI groups harbored similar degree of proteinuria (0.25 ± 0.95 grams per day versus 0.19 ± 0.57 grams per day, \( P = 0.467 \)).

As shown in Table 2, individuals with supranormal HGI harbored a higher prevalence of multiple vessel disease relative to those with subnormal HGI (Odds ratio (OR): 3.9, 95% confidence interval (CI): 2.64 - 5.98, \( P < 0.001 \)). Moreover, the supranormal HGI group more frequently demonstrated lesions involving the left anterior descending artery (OR: 3.0, 95% CI: 1.97 - 4.66, \( P < 0.001 \)). As illustrated in Table 3, the length of hospitalization was similar between groups. Intriguingly, people with supranormal HGI demonstrated a trend towards requiring multiple stent deployment relative to those with subnormal HGI (23.0% versus 16.7%, \( P = 0.067 \)).

A multivariate regression analysis was performed using age, systolic blood pressure, low density and high density lipoprotein cholesterol, triglycerides, and HGI to determine the effect of these
variables on CHD. The standardized coefficient of each variable in association with cardiovascular disease is shown in Table 4, which identifies HGI as a prominent contributor to the extent of CHD ($\beta = 0.31; P < 0.001$).

A logistic regression analysis also demonstrated the association between HGI and extent of CHD. After adjusting for potential confounding variables, participants with supranormal HGI nonetheless harbored a higher risk of multiple vessel disease (OR: 2.62, 95% CI: 1.97-3.49, $P < 0.001$) compared with those with subnormal HGI.

4 Discussion

Cardiovascular disease affects a considerable proportion of people with T2D and detracts from their survival (Naito & Kasai, 2015; White et al., 2016). However, HbA1c measurements delineated only a fraction of cardiovascular disease risk (Rawshani et al., 2017). This study demonstrated that HGI consistently correlated with the extent of CHD in T2D. As observed by previous investigators, people with elevated HGI harbor an accelerated rate of protein glycation with subsequent endothelial injury (Nayak et al., 2011). Supranormal HGI may also reflect an excess of advanced glycosylation end products that arise from chronic hyperglycemia (Singh et al., 2014).

Researchers have postulated that specific patterns of glucose variation, as measured by HGI, constitute a distinctive risk factor for diabetic complications. Whereas HbA1c measures protein glycosylation within the red blood cell, diabetic complications may arise from protein glycation in both the extracellular and intracellular space. HGI was suggested as an indicator of the rate of extracellular protein glycation (Leslie & Cohen, 2009). Another potential explanation for a
supranormal HGI may be postprandial hyperglycemia, which raises the measured HbA1c above that predicted from FPG (Rizza, 2010; Riddle & Gerstein, 2015). Indeed, several studies have implicated hyperglycemia after meals in the development of cardiovascular disease (Cavalot et al., 2011; Node & Inoue, 2009; Ceriello, 2009). These findings were corroborated by the observation in this study that different HGI subgroups, potentially reflecting the degree of postprandial hyperglycemia, consistently correlated with the extent of CHD.

Whereas researchers previously identified an association between HGI and a composite index of cardiac, cerebral, and peripheral vascular events (Nayak et al., 2013; Hempe et al., 2015), this study provides novel information by focusing on the link between HGI and coronary vascular disease. An implication of this study is that cardiovascular risk assessment may be refined by HGI, particularly in individuals with similar baseline HbA1c. Furthermore, people with supranormal HGI who experience angina pectoris are at risk of CHD and should receive comprehensive examination. Considering the aforementioned link between postprandial hyperglycemia, HGI, and cardiovascular disease risk (Riddle & Gerstein, 2015; Raz et al., 2011), controlling postprandial hyperglycemia in individuals with supranormal HGI may be an appropriate therapeutic approach to attenuate CHD.

This study benefits from an objective assessment of macrovascular disease by CAG. Conventional risk factors for CHD were similar between the HGI subgroups. Furthermore, potential confounding effects of lipid-lowering therapy were reduced by enrolling recipients of HMG-CoA reductase inhibitors since diabetes outset (Jellinger et al., 2012). Data regarding cardiovascular risk factors such as dyslipidemia, blood pressure, and cigarette smoking were available for the entire study population.
Several limitations may arise from the study design. Degree of insulin resistance and mode of antidiabetic treatment may influence CHD but were not uniformly available (Syed Ikmal et al., 2013; Marso et al., 2016). Although participants received comprehensive diabetes education by certified educators, adherence to lifestyle intervention could not be ascertained. Body weight may influence cardiovascular risk, but investigators previously demonstrated that high-risk coronary anatomy was paradoxically less frequent in obese patients (Rubinshtein et al., 2006). The relationship between body weight and CHD remains uncertain and was not assessed in this study. Participants were diagnosed with T2D in the preceding ten years according to their medical records, but precise disease duration could not be confirmed due to the latent nature of T2D. Finally, any complication associated with HGI may be difficult to dissect from the influence of HbA1c (Sacks, Nathan & Lachin, 2011).

5 Conclusions

HGI consistently correlated with the extent of CHD in individuals with T2D. People with supranormal HGI harbored a higher prevalence of multiple vessel disease compared to those with subnormal HGI, which may further complicate their management. Undeniably, a correlation between HGI and CHD does not imply causation, and further studies are necessary to explore the physiologic basis of this glycation index. Overall, HGI provides useful information regarding cardiovascular disease risk in T2D.

References

Chen L, Magliano DJ, Zimmet PZ. 2011. The worldwide epidemiology of type 2 diabetes
Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. 2010. Prevalence of diabetes among men and women in China. *N Engl J Med* 362:1090-1101.

Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S, Chalmers J. 2017. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. *Cardiovasc Diabetol* 16:95.

Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. 2015. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. *Lancet Diabetes Endocrinol* 3:105–113.

Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. 2007. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. *Exp Clin Cardiol* 12:17–28.

Laakso M. 2010. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. *Diabetes Care* 33:442-449.

Fox CS. 2010. Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. *Trends Cardiovasc Med* 20:90-95.

Soros AA, Chalew SA, McCarter RJ, Shepard R, Hempe JM. 2010. Hemoglobin glycation index: a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients. *Pediatr Diabetes* 11:455-461.

Nayak AU, Nevill AM, Bassett P, Singh BM. 2013. Association of glycation gap with mortality and vascular complications in diabetes. *Diabetes Care* 36:3247-3253.
Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. 2015. The hemoglobin
glycation index identifies subpopulations with harms or benefits from intensive treatment in the
ACCORD trial. *Diabetes Care* **38**:1067-1074.

Leopold JA, Faxon DP. 2015. Diagnostic cardiac catheterization and coronary angiography. In;
Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, ed. *Harrison's Principles of
Internal Medicine, 19th edition*. New York: McGraw-Hill.

Tazaki J, Shiomi H, Morimoto T, Imai M, Yamaji K, Sakata R, Okabayashi H, Hanyu M,
Shimamoto M, Nishiwaki N, Komiya T, Kimura T; CREDO-Kyoto PCI/CABG registry
cohort-2 investigators. 2013. Three-year outcome after percutaneous coronary intervention and
coronary artery bypass grafting in patients with triple-vessel coronary artery disease: observations
from the CREDO-Kyoto PCI/CABG registry cohort-2. *EuroIntervention* **9**:437-445.

Naito R, Kasai T. 2015. Coronary artery disease in type 2 diabetes mellitus: Recent treatment
strategies and future perspectives. *World J Cardiol.* **7**:119-124.

White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE,
Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP; EXAMINE Investigators.
2016. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary
syndromes from the EXAMINE trial. *Diabetes Care* **39**:1267-1273.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK,
Sattar N, Rosengren A, Gudbjörnsdóttir S. 2017. Mortality and cardiovascular disease in type
1 and type 2 diabetes. *N Engl J Med* **376**:1407-1418.

Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. 2011. Evidence for consistency
of the glycation gap in diabetes. *Diabetes Care* **34**:1712-1716.

Singh VP, Bali A, Singh N, Jaggi AS. 2014. Advanced glycation end products and diabetic
complications. *Korean J Physiol Pharmacol* **18**:1-14.

Leslie RD, Cohen RM. 2009. Biologic variability in plasma glucose, hemoglobin A1c, and
advanced glycation end products associated with diabetes complications. *J Diabetes Sci Technol* 3:635-643.

Rizza RA. 2010. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. *Diabetes* 59: 2697-2707.

Riddle MC, Gerstein HC. 2015. Comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. *Diabetes Care* 38: e170-171.

Cavalot F, Pagliarino A, Valle M, Di Martino L, Bonomo K, Massucco P, Anfossi G, Trovati M. 2011. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. *Diabetes Care* 34:2237-2243.

Node K, Inoue T. 2009. Postprandial hyperglycemia as an etiological factor in vascular failure. *Cardiovasc Diabetol* 8:23.

Ceriello A. 2009. Postprandial hyperglycemia and cardiovascular disease: Is the HEART2D study the answer? *Diabetes Care* 32:521-522.

Raz I, Ceriello A, Wilson PW, Battoui C, Su EW, Kerr L, Jones CA, Milicevic Z, Jacober SJ. 2011. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. *Diabetes Care* 34:1511-1513.

Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. 2012. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. *Endocr Pract* 18:1-78.

Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. 2013. Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. 2016. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 375:311-322.

Rubinshtein R, Halon DA, Jaffe R, Shahla J, Lewis BS. 2006. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angiography. *Am J Cardiol* 97:1277-1280.

Sacks DB, Nathan DM, Lachin JM. 2011. Gaps in the glycation gap hypothesis. *Clin Chem* 57:150-152.
### Table 1 (on next page)

Demographic characteristics of the hemoglobin glycation index groups

Data are expressed as mean with standard deviation for continuous variables and number (%) for categorical variables. Hemoglobin glycation index is defined as the difference between an individual’s observed HbA1c and the HbA1c predicted from fasting plasma glucose. HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; SCr, serum creatinine; HGI, hemoglobin glycation index.
Demographic characteristics of the hemoglobin glycation index groups

|                              | HGI < 0   | HGI ≥ 0   | P value |
|------------------------------|-----------|-----------|---------|
|                              | (n = 180) | (n = 243) |         |
| HbA1c (%)                    | 7.5 ± 1.0 | 7.4 ± 1.1 | 0.80    |
| Age (years)                  | 67 ± 11   | 67 ± 10   | 0.56    |
| Gender                       |           |           |         |
| Female                       | 84 (46.7%)| 98 (40.3%)| 0.19    |
| Male                         | 96 (53.3%)| 145 (59.7%)|         |
| HDL-C (mg/dL)                | 42 ± 12   | 39 ± 14   | 0.06    |
| LDL-C (mg/dL)                | 88 ± 30   | 91 ± 34   | 0.38    |
| TG (mg/dL)                   | 159 ± 126 | 155 ± 109 | 0.76    |
| SCr (mg/dL)                  | 1.5 ± 1.7 | 1.6 ± 1.7 | 0.52    |
| Cigarette smoking            |           |           |         |
| Yes                          | 138 (76.7%)| 189 (77.8%)| 0.79    |
| No                           | 42 (23.3%)| 54 (22.2%)|         |
| Systolic blood pressure (mm Hg) | 136 ± 24 | 135 ± 19 | 0.65 |
| Proteinuria (g/day)          | 0.25 ± 0.95 | 0.19 ± 0.57 | 0.47 |
Table 2 (on next page)

Extent of coronary heart disease in hemoglobin glycation index groups

Data are expressed as number (%) for categorical variables. Hemoglobin glycation index is defined as the difference between an individual’s observed HbA1c and the HbA1c predicted from fasting plasma glucose. HGI, hemoglobin glycation index; LAD, left anterior descending artery; CI, confidence interval.
### Extent of coronary heart disease in hemoglobin glycation index groups

|                                | HGI < 0 (n = 180) | HGI ≥ 0 (n = 243) | Odds ratio | 95% CI     | P value |
|--------------------------------|-------------------|-------------------|------------|------------|---------|
| Arteriosclerosis or single vessel disease | 111 (61.7%)       | 70 (28.8%)        | 3.9        | 2.64 – 5.98 | < 0.001 |
| Multiple vessel disease         | 69 (38.3%)        | 173 (71.2%)       |            |            |         |
| Left anterior descending artery disease | 102 (56.7%)       | 194 (79.8%)       | 3.0        | 1.97 – 4.66 | < 0.001 |
Table 3 (on next page)

Clinical outcome of the hemoglobin glycation index groups

Data are expressed as mean with standard deviation for continuous variables and number (%) for categorical variables. Hemoglobin glycation index is defined as the difference between an individual’s observed HbA1c and the HbA1c predicted from fasting plasma glucose. HGI, hemoglobin glycation index.
Clinical outcome of the hemoglobin glycation index groups

|                           | HGI < 0  (n = 180) | HGI ≥ 0 (n = 243) | P value |
|---------------------------|---------------------|-------------------|---------|
| Length of stay (days)     | 2.8 ± 2.3           | 3.0 ± 2.5         | 0.41    |
| Number of stent           |                     |                   |         |
| None or single            | 150 (83.3%)         | 187 (77.0%)       | 0.067   |
| Multiple                  | 30 (16.7%)          | 56 (23.0%)        |         |
Table 4 (on next page)

Multivariate regression analysis evaluating coronary heart disease as dependent variable
Multivariate regression analysis evaluating coronary heart disease as dependent variable

| Independent variables                      | β coefficient | P value |
|--------------------------------------------|---------------|---------|
| Age                                        | 0.054         | 0.14    |
| Systolic blood pressure                    | -0.058        | 0.12    |
| Low density lipoprotein cholesterol        | 0.051         | 0.15    |
| High density lipoprotein cholesterol       | -0.06         | 0.11    |
| Triglycerides                              | -0.084        | 0.041   |
| Hemoglobin glycation index                 | 0.31          | < 0.001 |
Figure 1

Relationship between hemoglobin A1c and fasting plasma glucose

Linear regression for the calculation of predicted hemoglobin A1c from measured hemoglobin A1c and fasting plasma glucose.
Figure 2

Enrollment protocol of the study

Enrollment protocol of the study with number and reason for candidate exclusion.

480 Individuals assessed for eligibility

57 Excluded
20 No statin prescription
32 Coronary angiography prior to study
5 No concomitant fasting glucose and hemoglobin A1c level

423 Received baseline blood test three months prior to angiography

423 Enrolled

243 with hemoglobin glycation index $\geq 0$ received coronary angiography

180 with hemoglobin glycation index $< 0$ received coronary angiography